Study Stopped
Investigator taking position at another university-0 enrolled under this protocol.
Hepatocyte Transplantation in Liver Failure
The Use of Human Hepatocyte Transplantation as a Life Support Bridge in Terminal Liver Failure.
1 other identifier
interventional
N/A
1 country
1
Brief Summary
The investigators research will examine the safety and efficacy of hepatocyte transplantation in the patient with acute liver failure without history of chronic disease. The investigators will study the effectiveness in providing a bridge of support for patient survival until whole organ transplantation is possible. This support may also be a bridge to recovery; by allowing the native liver to recover so that orthotopic liver transplant is not necessary. The investigators will also study the safety and efficacy of hepatocyte transplantation in the patient with chronic liver disease. Underlying etiologies of chronic disease may arise from cirrhosis, fibrosis or inherited metabolic disorders. The investigators will examine cell transplantation in end-stage patients not eligible for whole organ transplant. These patients may benefit with an amelioration of symptoms that will allow other therapeutic treatments. The investigators study will also examine the ability of transplanted hepatocytes to treat inherited metabolic diseases (ex., Crigler-Najjar Disease, Familial Hypercholesterolemia, Urea Cycle Disorders). Cell transplant may also act as a 'bridge' to whole organ transplant or improve function, permitting easier disease control through traditional therapy.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
Started Jun 2014
Longer than P75 for phase_1
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
December 5, 2008
CompletedFirst Posted
Study publicly available on registry
December 9, 2008
CompletedStudy Start
First participant enrolled
June 1, 2014
CompletedPrimary Completion
Last participant's last visit for primary outcome
June 1, 2016
CompletedStudy Completion
Last participant's last visit for all outcomes
June 1, 2018
CompletedAugust 5, 2014
August 1, 2014
2 years
December 5, 2008
August 1, 2014
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
The functional capability of transplanted hepatocytes to assume function in the native liver.
Outcome measurements will be assessed weekly through week two post transplant, then monthly through month 12, then every six months.
Study Arms (1)
Hepatocyte Transplantation
EXPERIMENTALHepatocyte Transplantation through single donor will be transplanted into the liver via intraportal or intrasplenic routes.
Interventions
Briefly, prepared hepatocytes from a single donor will be transplanted into the liver via intraportal or intrasplenic routes.
Eligibility Criteria
You may not qualify if:
- Any systemic infection
- Unstable coronary artery disease
- HIV infection
- Preformed antibodies to class antigens that are present on all available donor samples (Only cells from an ABO-compatible donor with no HLA Class I antigen to which the recipient has preformed antibodies will be selected for transplant.)
- Hepatopulmonary disease (Room air Pa02 ≤ 60 mmHg)
- Testing positive for Hepatitis B Surface Antigen (HBsAg), Hepatitis Be antigen (HBeAg) or Hepatitis B Virus by DNA and unable to receive or pay for Hepatitis B treatment.
- Any current or anticipated contraindication for the use of tacrolimus and cyclosporine, methylprednisolone or prednisone.
- Female patients who are breast feeding
- Any medical condition that, in the opinion of the investigator, makes the patient unsuitable for participation in this trial.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Virginia Commonwealth University Health System
Richmond, Virginia, 23298, United States
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Robert A Fisher, M.D.
Virginia Commonwealth University Health System
Study Design
- Study Type
- interventional
- Phase
- phase 1
- Allocation
- NA
- Masking
- NONE
- Purpose
- TREATMENT
- Intervention Model
- SINGLE GROUP
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
December 5, 2008
First Posted
December 9, 2008
Study Start
June 1, 2014
Primary Completion
June 1, 2016
Study Completion
June 1, 2018
Last Updated
August 5, 2014
Record last verified: 2014-08